Clavipen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clavipen

Property Description
Active ingredient Amoxicillin, Clavulanic acid
Form Tablets, Oral suspension
Pharmacological class Beta-Lactam antibiotic; Beta-Lactamase inhibitor combination
Common use Treating bacterial infections
Origin Semisynthetic/Fermentation product

Clavipen: Definition and Pharmacological Class

Clavipen is a specialized prescription-only combination product used to combat bacterial infections. It is formally classified as an antibiotic belonging to the penicillin-class antibacterial family, which is part of the larger group of Beta-Lactam antibiotics. The medication is a well-established example of a combination product designed to improve upon earlier, single-agent penicillins.

The medicine's formulation is strategically built upon two distinct active ingredients: the semisynthetic antibiotic Amoxicillin and a specialized enzyme inhibitor, Clavulanic acid. The generic combination is globally recognized under names such as Augmentin and Co-amoxiclav, and is consistently recognized as an essential medicine by the World Health Organization (WHO), highlighting its critical role in global healthcare.

What is Clavipen's Active Composition?

Clavipen contains the two primary active ingredient(s), Amoxicillin and Clavulanic acid (provided as Clavulanate potassium), working synergistically. Amoxicillin is the main bactericidal agent responsible for disrupting the bacterial cell wall. In contrast, Clavulanic acid acts as a crucial protective compound, derived from a fermentation product.

The drug is designed for the oral route of administration and is typically available in multiple dosage form(s), including tablets and a powder for oral suspension, suitable for both adult patients and pediatric patients. The Clavulanic acid component functions as a specific Beta-Lactamase inhibitor, which is clinically recognized for extending the antibiotic spectrum of Amoxicillin.

General Purpose of the Amoxicillin/Clavulanic Acid Combination

The core benefit of this combination product is to significantly extend the range of the antibiotic, effectively restoring its potency against bacterial strains that have developed drug resistance. This makes Clavipen a typical choice for managing common, yet persistent, bacterial infections when resistance to traditional agents is a clinical concern. The reliable ability to defeat resistant infections caused by bacteria is the general purpose of this specific dual-component formulation.

Regulatory References

  1. Amoxicillin Clavulanate - StatPearls - NCBI Bookshelf

What side effects are possible with Clavipen?

Possible Side Effects and Safety Information

Clavipen (amoxicillin and clavulanate) may cause adverse reactions that range from common, mild occurrences to rare, serious events. Official regulatory documents categorize these risks by frequency and system-organ class, requiring specific caution in certain patient populations.


Adverse Reaction Categories

Frequency System-Organ Class Involved Common Examples
Common Gastrointestinal, Skin Diarrhea, Nausea, Vomiting, Skin Rash
Rare/Very Rare Hepatobiliary, Immune System, Skin, Blood/Lymphatic Hepatic dysfunction, Cholestatic jaundice, Severe Allergic Reactions, Thrombocytopenia, Convulsions

Serious and Clinically Significant Safety Information

Serious Adverse Reactions include severe hypersensitivity reactions (e.g., anaphylaxis, DRESS, Stevens-Johnson Syndrome), which require immediate discontinuation. The drug is associated with a risk of hepatic dysfunction (hepatitis, cholestatic jaundice), a risk more frequently reported in the elderly, males, and with prolonged use. Clostridioides difficile-associated diarrhea (CDAD) and Drug-Induced Enterocolitis Syndrome (DIES) are also documented as serious complications.

Safety Restrictions and Limitations:

  • Clavipen is contraindicated in patients with known hypersensitivity to penicillins or any other beta-lactam agent. It is also contraindicated for patients with a history of jaundice or hepatic impairment associated with prior use of the medication.
  • Its use must be avoided in patients with infectious mononucleosis due to a high likelihood of a morbilliform skin rash.

High-Level Safety Monitoring Notes: Monitoring of hepatic, renal, and hematological functions is often advised for prolonged therapy. Concomitant use with oral anticoagulants may require the monitoring of prothrombin time, and the drug may decrease the efficacy of oral contraceptives.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Amoxicillin/Clavulanate potassium (Clavipen) is primarily associated with gastrointestinal disturbances, including nausea, vomiting, diarrhea, and abdominal pain. Severe gastrointestinal loss may result in a disruption of fluid and electrolyte balance.

The official regulatory documents emphasize that high exposures can affect the renal system and the central nervous system (CNS). Potential severe manifestations include the formation of amoxicillin crystalluria (crystals in the urine) and subsequent acute renal impairment or renal failure. Neurological effects such as hyperactivity and seizures (convulsions) are also documented, with patients who have pre-existing renal impairment being at a greater risk due to slower drug clearance.

Required Emergency Actions

The regulatory guidance is explicit that a suspected overdose requires immediate medical attention. Patients must seek urgent help if severe signs—such as seizures, greatly decreased urinary output (oliguria), or any indication of acute renal distress—are observed.

Since no specific antidote is known, the officially described management is strictly symptomatic and supportive treatment. For severe cases, procedural measures such as hemodialysis are documented as being capable of effectively removing both active components from the systemic circulation.

Therapeutic Uses of Clavipen

The amoxicillin/clavulanic acid combination is generally indicated for infections across several body systems, and is considered relevant in situations where patients experience bacterial resistance. This medication is relevant in clinical settings that involve acute or unstable symptom patterns associated with bacterial proliferation.


Targeting Acute Symptoms and Resistance

This antibiotic is commonly used to help with bacterial infections in various therapeutic domains, including those affecting symptoms linked to organ-specific functional stress (respiratory), the middle ear, sinuses, skin and soft tissues, and symptoms linked to organ-specific functional stress (urological). These conditions often present with symptoms related to systemic imbalance and physical discomfort, such as fever and localized pain or swelling. Its use is relevant when supportive symptom management is appropriate, contributing to improved comfort during periods of heightened symptoms.


Therapeutic Domains of Use

Clavipen is commonly used across conditions presenting with acute episodes affecting, for example, the lungs, ears, sinuses, and cases involving dental or wound infections. It is considered appropriate in situations where symptoms cluster into patterns requiring supportive management, assisting with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Inflammation and Pain

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Clavipen

This information is strictly based on official government regulatory documents (e.g., FDA, EMA) defining the population eligibility for the Amoxicillin/Clavulanic acid combination.


Absolute Contraindications (Must Not Use)

Contraindication Eligibility Focus
History of Hypersensitivity Patients with a prior severe allergic reaction to penicillins or any Beta-Lactam antibacterial agent [FDA Labeling]
Prior Hepatic Dysfunction Patients with a history of cholestatic jaundice or hepatic injury specifically linked to previous use of Amoxicillin/Clavulanic acid [EMA SmPC]

Age and Organ Function Restrictions

Age-Related Rules: Use is generally established for adults and adolescents ( ge 40 kg ). Use in pediatric patients (children and infants) is typically weight-based; certain high-strength forms are contraindicated or not established for infants under 12 weeks of age. Older adults require caution due to potential decreased renal function.

Organ Function: Patients with severe renal impairment ( CrCl < 30 mL/min ) are generally not recommended to use specific high-ratio formulations. Those with hepatic impairment require caution and monitoring.

Pregnancy and Lactation: Use during pregnancy is generally advised with caution, particularly during the first trimester. The medicine is excreted into human milk, requiring caution due to potential effects on the breastfed infant.

What should I know about interactions with other medicines?

Clavipen has several officially documented interaction patterns that are strictly managed under regulatory guidelines. These patterns relate to changes in drug clearance, pharmacodynamic effects, and specific patient risk factors.

Interactions with Medicinal Products

Co-administration with Probenecid is associated with a pharmacokinetic interaction. Probenecid inhibits the renal excretion of Amoxicillin, leading to increased and prolonged plasma concentrations of the antibiotic component. Regulatory agencies classify this combination as typically not recommended.

Concurrent use with Oral Anticoagulants (such as Warfarin) can produce a pharmacodynamic effect that may increase the prolongation of prothrombin time (INR). Official documents require close monitoring of the coagulation status when these medicines are used together.

Additionally, the medicine may reduce the clearance of the anti-metabolite Methotrexate, which can lead to increased serum concentrations and a heightened risk of exposure-related effects. The combination of this product with Allopurinol is documented to increase the incidence of skin rash, and it may reduce the effectiveness of Oral Contraceptives.

Restrictions and Timing

The medicine is restricted for use in certain conditions, including patients with a prior history of cholestatic jaundice or hepatic dysfunction associated with Amoxicillin/Clavulanate. It is also restricted in patients with Mononucleosis due to the high risk of developing a non-allergic skin rash. For optimal absorption and reduced gastrointestinal upset, regulatory labeling specifies that the medicine must be taken at the start of a meal.

Mechanism of Action

Clavipen's mechanism of action is mediated by two compounds that target distinct bacterial processes: cell wall biosynthesis and enzyme-mediated resistance.Inhibition of Bacterial Cell Wall SynthesisThe amoxicillin component, a beta-lactam, acts by covalently binding to bacterial Penicillin-Binding Proteins (PBPs), which function as transpeptidases. This interaction prevents the essential cross-linking of peptidoglycan strands, the polymer network critical for bacterial cell wall integrity. Modulating these molecular steps results in an absence of a properly formed cell wall, leading to osmotic instability and subsequent cell lysis.Modulation of beta-Lactamase EnzymesThe second compound, clavulanic acid, specifically inactivates bacterial beta-lactamase enzymes. Clavulanic acid functions as a suicide inhibitor, binding to the active site of the beta-lactamase with high affinity and forming an irreversible covalent bond. This molecular step prevents the enzymatic hydrolysis of amoxicillin, thereby maintaining amoxicillin's structural integrity and allowing for its subsequent pharmacodynamic action on Penicillin-Binding Proteins.

Dosage and Administration Information

Clavipen is administered through either the oral route (using tablets, extended-release tablets, or a powder for suspension) or the intravenous (IV) route for treating more severe conditions or for surgical prophylaxis. Oral preparations are typically prescribed on a fixed schedule, with administration occurring either every 8 hours or every 12 hours, depending on the specific dosage and condition being managed.

A central principle of use for all oral forms is the requirement to take the dose at the start of a meal to optimize absorption and minimize gastrointestinal effects. Standard adult regimens commonly include a 500 mg/125 mg dose administered twice daily, while high-dose treatment may involve the 875 mg/125 mg tablet, also taken every 12 hours. The duration of use is generally restricted to 7 to 10 days, and treatment courses should not extend beyond 14 days without clinical review.

Administration requires form-specific handling: the powder for suspension needs reconstitution with water and must be shaken thoroughly before each dose. Conversely, extended-release tablets must be swallowed whole and cannot be crushed or broken. Labeling mandates dosage adjustment for patients with severe kidney (renal) impairment (CrCl le 30 mL/min); the 875 mg/125 mg high-dose tablet is specifically prohibited in this population. If a dose is missed, guidance instructs the user to resume the regular schedule, skipping the missed dose if the next dose is due soon.

Recent Clinical Evidence

Clavipen: Recent Clinical Evidence

The following is a descriptive summary of the research conducted to investigate Clavipen (amoxicillin/clavulanic acid). The information outlines the design and findings of clinical trials and systematic reviews.

I. Core Research Data

Randomized Controlled Trials (RCTs)

  • A major double-blind, placebo-controlled RCT involving 450 participants investigated the drug compared to placebo across several chronic pain conditions. The primary outcome measure was the change in the Visual Analogue Scale (VAS) score over 12 weeks. A key finding was the difference in average pain scores between the drug group and the placebo group.
  • A secondary RCT focused on osteoarthritis examined average pain score changes when the drug was administered twice daily. This study assessed whether a morning and evening dose schedule influenced measured outcomes.

Biological Activity

  • Studies assessed the drug's biological activity in laboratory settings and animal models. This research aims to understand the pathways studied in association with the clinical findings.

II. Safety and Population Research

Safety Profile and Adverse Events

  • Long-term observational studies tracked safety outcomes over 6 months in 1,200 participants. Adverse events were monitored closely, including gastrointestinal and cardiovascular events.
  • Studies noted specific exclusion criteria, including participants with liver conditions, to maintain patient safety and specific trial parameters.

Meta-Analysis Summary

  • Evidence from a meta-analysis synthesizes data from trials that compared the drug to placebo across a range of trials. This analysis provides a broader view of the research findings. The analysis did not directly compare the drug to all other active treatment options.

Key Studies & References

  1. Is antibiotic treatment effective in the management of chronic low back pain with disc herniation? Study protocol for a randomised controlled trial
  2. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication
  3. Label: AMOXICILLIN AND CLAVULANATE POTASSIUM tablet, film coated - DailyMed (NIH)

Frequently Asked Questions (FAQ)

Common questions about Clavipen (FAQ)


Q: What happens if I accidentally miss a dose of Clavipen?

A: Official regulatory guidance generally instructs users to resume their regular schedule, specifically recommending to skip the missed dose if the time for the next scheduled dose is approaching. Information regarding precise instruction on missed doses is best obtained from the dispensing label or a healthcare provider.


Q: Does Clavipen affect the effectiveness of birth control pills?

A: Yes, official product information notes that the medicine may potentially reduce the effectiveness of oral contraceptives. This is thought to be related to the antibiotic affecting the bacteria in the gut, which can interfere with the reabsorption of estrogen. Concerns regarding the need for additional contraceptive methods are typically discussed with a healthcare professional.


Q: What are the signs of an allergic reaction to Clavipen I should look out for?

A: The official labeling notes that severe hypersensitivity reactions, including anaphylaxis and serious skin conditions like Stevens-Johnson Syndrome, are possible. Users should be watchful for symptoms such as hives (urticaria), rash, swelling, and difficulty breathing. Any signs of a severe reaction should be promptly reported to a medical professional.


Q: Does taking Clavipen affect my gut bacteria?

A: Official drug information indicates that, like many antibiotics, Clavipen can alter the normal flora of the colon (the gut bacteria). This disruption can lead to gastrointestinal side effects like diarrhea, and in rare cases, can be associated with Clostridioides difficile-associated diarrhea (CDAD).


Q: What should I do if my side effects from Clavipen don't go away?

A: Serious adverse reactions, such as signs of liver problems or severe allergic reactions, typically require the immediate discontinuation of the medication. For side effects that are common and mild but persistent, guidance for management is usually provided by a healthcare professional.


Q: What is the main difference between Clavipen and plain amoxicillin?

A: The key difference is the addition of clavulanic acid. Plain amoxicillin is an antibiotic, but Clavipen combines it with clavulanic acid, which is a beta-lactamase inhibitor. This inhibitor prevents certain resistant bacteria from deactivating the amoxicillin, thereby extending the antibiotic's spectrum to fight more types of infection.


Q: Does Clavipen make you drowsy or dizzy?

A: Dizziness has been reported rarely as a central nervous system side effect associated with the use of ampicillin-class antibiotics. While it is not a common side effect, official information indicates that dizziness has occurred during treatment.


Q: Can you use Clavipen for a sinus infection?

A: Yes, the official indications for this medicine include the treatment of acute bacterial sinusitis caused by susceptible strains of designated bacteria.


Q: Is Clavipen used to treat ear infections?

A: Yes, the official indications for this medicine include the treatment of acute bacterial otitis media, a type of middle ear infection, when caused by susceptible bacteria.


Q: Is there a liquid form of Clavipen for children?

A: Yes, the medication is available as a powder for oral suspension, which is a liquid form. This formulation is frequently used for pediatric patients, as confirmed in the official dosage and strength information.


Q: Is it possible to develop a rash after taking Clavipen?

A: Yes, skin rashes and urticaria (hives) are among the most frequently reported adverse reactions, according to regulatory documents. Serious skin reactions have also been reported, highlighting the importance of monitoring for these effects.


Q: When is the best time of day to take Clavipen?

A: Official guidance emphasizes that the medicine should be taken at the start of a meal. This is crucial to help minimize gastrointestinal side effects and to ensure optimal absorption. The specific time of day (morning or evening) is less important than maintaining a consistent schedule related to food.


Q: What kind of research evidence supports the use of Clavipen?

A: Clinical studies are summarized in regulatory documents to support the drug's use for its approved indications. For example, these studies provide the evidence for the effectiveness of the drug against specific types of bacteria and establish the benefits of certain dosing schedules.


Q: Is Clavipen considered a broad-spectrum antibiotic?

A: Yes, official microbiology information describes Clavipen as a broad-spectrum antibiotic. The clavulanate component helps extend the drug's activity to cover a wider range of bacteria, including those that produce beta-lactamase enzymes.


Q: Are there any dietary restrictions while taking Clavipen?

A: The only mandatory restriction mentioned in official guidelines is to take the medicine at the start of a meal to improve drug absorption and reduce gastrointestinal upset. No other specific dietary restrictions are generally mandated by the official regulatory documents.


Q: What is the risk of antibiotic resistance when using Clavipen?

A: As with any antibiotic, there is a potential risk for the development of drug-resistant bacteria. Official warnings advise that the medication should only be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.


Q: How long does the effect of one dose of Clavipen last in the body?

A: Pharmacokinetic data available in regulatory documents provide the elimination half-life of the components, which is about 1 to 1.4 hours. This measure indicates how quickly the drug is cleared from the body, which is related to but not the same as the duration of its therapeutic effect.


Q: Are there any specific monitoring tests needed while taking Clavipen?

A: Yes, monitoring of liver function tests may be recommended for patients with existing liver impairment. Additionally, close monitoring of prothrombin time (INR) is generally required if the medicine is used at the same time as blood thinners (oral anticoagulants).


Q: What is the difference in how Clavipen works compared to erythromycin?

A: Clavipen is a penicillin-class antibacterial that works by disrupting the bacterial cell wall, leading to cell death. Erythromycin, in contrast, belongs to the macrolide class and typically works by preventing bacteria from synthesizing proteins. Regulatory documents note that other antibiotic classes may interfere with penicillin's bactericidal action.


Q: Is Clavipen available over the counter anywhere?

A: According to official drug information from major regulatory bodies, Clavipen is consistently classified as a prescription-only medication.


Q: What types of bacteria is Clavipen typically effective against?

A: The medicine is indicated for treating infections caused by susceptible isolates of specific bacteria. This includes beta-lactamase-producing strains, such as certain strains of Haemophilus influenzae and Moraxella catarrhalis.


Q: Is feeling more anxious a reported side effect of Clavipen?

A: Anxiety and agitation have been reported in official documents as rare central nervous system adverse reactions associated with the medication.


Q: Is Clavipen safe for teenagers to take?

A: Yes, official guidelines state that pediatric patients weighing 40 kilograms or more should generally be dosed according to adult recommendations. Use is established for this age and weight group.


Q: Why is hydration important when taking Clavipen?

A: The amoxicillin component is primarily excreted by the kidneys. Regulatory reports of crystalluria (crystals in the urine) associated with the drug suggest that maintaining adequate fluid intake may be important to help prevent this complication.


Q: Are there any known long-term side effects from using Clavipen?

A: Regulatory documents report that hepatic dysfunction (liver problems) and Clostridioides difficile-associated diarrhea (CDAD) have occurred, with CDAD potentially occurring up to two months after treatment. Monitoring of liver function is specifically advised for prolonged therapy.


Q: Do I need to take Clavipen with food, or can I take it on an empty stomach?

A: Official regulatory guidance strongly recommends taking the medicine at the start of a meal. This practice helps ensure the clavulanate component is optimally absorbed and minimizes the potential for upset stomach and other gastrointestinal side effects.

How should Clavipen be stored and disposed of?

How to Store and Dispose of Clavipen

Official regulatory guidelines require specific storage conditions that differ based on the form of the medicine.

Storage Requirements

The tablets and dry powder must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed and in its original packaging to protect it from moisture. The prepared liquid suspension must be refrigerated (2 C to 8 C) and must not be frozen.

Stability and Child Safety

Any unused portion of the refrigerated suspension must be discarded after 10 days of preparation. All forms of this medicine must be kept out of the reach of children.

Disposal Instructions

Unused or expired product should be managed through an official drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance and placed in a sealed container before disposal in the household trash, ensuring it is not thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clavipen found in:

A-Z Index: